Skip to content

Trial to Assess Whether Computed Tomography Cardiac Angiography Can Improve Invasive Coronary Angiography in Bypass Surgery Patients

A Randomised Controlled Trial Assessing the Value of Computed Tomography Cardiac Angiography in Improving Patient Satisfaction and Reducing Contrast Load, Procedural Duration and Complications in Patients Who Had Previous Bypass Surgery Undergoing Coronary Angiography

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07022626
Acronym
BYPASS-CTCA
Enrollment
688
Registered
2025-06-15
Start date
2018-11-14
Completion date
2024-02-28
Last updated
2025-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Contrast-induced Nephropathy, Ischaemic Heart Disease

Keywords

Coronary Artery Bypass Grafts, Computed Tomography Coronary Angiography, Invasive Coronary Angiogram

Brief summary

A large number of patients with symptomatic ischaemic heart disease undergo coronary artery bypass grafting (CABG) to alleviate their symptoms and improve prognosis. Given the progressive nature of coronary disease, bypass grafts can narrow or block over time, leading to chest pain and the need for further invasive coronary angiography. Invasive coronary procedures in patients with bypass grafts can be more complicated due to the variation in bypass graft ostia. This can lead to longer procedure times, with higher doses of contrast and radiation and more discomfort for the patient. The aim of this study is to see if the use of computed tomography coronary angiography (CTCA) in patients with previous bypass grafts prior to invasive coronary angiography will help make their procedure safer and quicker.

Detailed description

The BYPASS-CTCA trial is a single-centre, randomised controlled trial, which plans to recruit 688 patients who have had previous bypass grafts and require invasive coronary angiography over a period of 30 months. Patients will be randomised to receive either computed tomography coronary angiography (CTCA) prior to their invasive coronary angiogram, or invasive coronary angiography alone. The primary endpoints will be the incidence of contrast induced nephropathy, the duration of the invasive coronary angiographic procedure and patient satisfaction. A number of secondary endpoints will also be looked at. Findings from BYPASS-CTCA will potentially demonstrate that a CTCA prior to invasive coronary angiography in this cohort of patients reduces the incidence of contrast-induced kidney injury, the length of procedure and improves patients satisfaction. The results of this trial may influence future clinical practice guidelines in coronary artery bypass graft patients undergoing invasive coronary procedures.

Interventions

PROCEDURECTCA

Computed Tomography Coronary Angiography (CTCA) performed prior to invasive coronary angiography (ICA)

Sponsors

Barts & The London NHS Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patients undergoing coronary angiography +/-Percutaneous coronary Intervention 2. Previous Coronary Artery Bypass Grafting (CABG) 3. Aged ≥18 4. Patients able and willing to give their written informed consent.

Exclusion criteria

1. Subjects presenting with ST elevation myocardial infarction, cardiogenic shock (systolic blood pressure \<80 mmHg for \>30 minutes, or requiring inotropes or emergency intra aortic balloon pump for hypotension treatment) or cardiopulmonary resuscitation. 2. Subjects with eGFR \<20ml/min or on renal replacement therapy. 3. Current life-threatening condition other than vascular disease that may prevent a subject completing the study. 4. Clinical instability including cardiogenic shock, hypotension (low blood pressure-systolic blood pressure less than 90 mmHg), sustained ventricular or atrial arrhythmia requiring intravenous medications. 5. Inability to tolerate beta-blockers, including those with chronic obstructive pulmonary disease or asthma, complete heart block, second-degree atrioventricular block 6. Known contrast dye allergy. 7. Pregnancy or unknown pregnancy status. 8. Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures). 9. Inability or refusal to provide informed consent. 10. Any inclusion criteria not met

Design outcomes

Primary

MeasureTime frameDescription
Procedural durationtimer started after the insertion of the arterial catheter and stopped when the catheters are removedTo measure the length of coronary angiographic procedure
Incidence of Contrast Induced Nephropathy48-72 hoursDefined by Kidney Disease: Improving Global Outcomes (KDIGO) criteria
Patient Satisfaction4-6 hours post angiogram +/- percutaneous coronary interventionPatient satisfaction measured by validated questionnaire

Secondary

MeasureTime frameDescription
Contrast AmountDuring procedureContrast amount (mls) administered during invasive coronary angiography
Radiation ExposureDuring procedureRadiation exposure (mSv) during invasive coronary angiography
Angiography Related ComplicationsDuring procedureAngiography related complications (such as coronary or aortic dissection, stroke, bleeding, vascular access complication)
Radial Access RateDuring procedureRadial access rates during invasive coronary angiography
Catheters UsedDuring procedureNumber of catheters used during invasive coronary angiography
Computed Tomography Cardiac Angiography AccuracyComputed Tomography Cardiac Angiography (CTCA)Accuracy of the computed tomography cardiac angiography scan for detecting graft patency
Number of grafts not identifiedDuring procedureNumber of grafts not identified during invasive coronary angiography
Cost effectiveness of computed tomography cardiac angiography12 monthsCost effectiveness of the intervention (per quality-adjusted life years) measured over 12 months of follow-up

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026